Resilience Capabilities Update May 2026: Large Molecule

Resilience is building a flexible, end-to-end CDMO network designed to accelerate complex biologics, cell therapy, and drug product programs from development through commercialization.

With operations spanning North America—including centers of excellence in Toronto for biologics and in the Philadelphia area for cell therapy—the organization combines experienced technical teams, integrated digital systems, and dedicated program leadership to streamline tech transfer and execution. Its capabilities cover cell line development, process optimization, fill-finish, device assembly, packaging, and global logistics, supported by strong regulatory track records and fast batch release timelines. Notably, the network emphasizes scalability, high on-time delivery, and the ability to overcome CMC bottlenecks.

For sponsors seeking speed, reliability, and partnership-driven execution, this overview highlights how modern CDMO infrastructure is evolving to meet growing pipeline demands. Explore the full session to see how these capabilities translate into measurable program outcomes.